| Name | Title | Contact Details |
|---|
Augmedics develops xvision™ – an Augmented-Reality Head-Mounted Display for spine surgery. xvision allows surgeons to see the patient`s anatomy through skin and tissue, as if they had "X-Ray Vision". Based on Augmedics` patented technology, the xvision system can project the patient`s anatomy, in real time, directly onto the surgeon`s retina, with surgical precision and outstanding depth perception. xvision will increase safety in surgery, reduce x-ray radiation, and facilitate minimally invasive procedures.
Wicab is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kestra Medical Technologies is a venture backed, medical device start up company located in Washington State providing innovative, intuitive medical technologies to protect and support at-risk patients.
Centurion Medical Products is a Williamston, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.